Literature DB >> 22003441

What is the functional role of the thalidomide binding protein cereblon?

Xiu-Bao Chang1, A Keith Stewart.   

Abstract

It has been found that nonsense mutation R419X of cereblon (CRBN) is associated with autosomal recessive non-syndromic mental retardation. Further experiments showed that CRBN binds to the cytosolic C-terminus of large-conductance Ca(++) activated potassium channel (BK(Ca)) α-subunit and the cytosolic C-terminus of a voltage-gated chloride channel-2 (ClC-2), suggesting that CRBN may play a role in memory and learning via regulating the assembly and surface expression of BK(Ca) and ClC-2 channels. In addition, it has also been found that CRBN directly interacts with the α1 subunit of AMP-activated protein kinase (AMPK) and prevents formation of a functional holoenzyme with regulatory subunits β and γ. Since AMPK is a master sensor of energy balance that inhibits ATP-consuming anabolic pathways and increases ATP-producing catabolic pathways, binding of CRBN with α1 subunit of AMPK may play a role in these pathways by regulating the function of AMPK. Furthermore, CRBN interacts with damaged DNA binding protein 1 and forms an E3 ubiquitin ligase complex with Cullin 4 where it functions as a substrate receptor in which the proteins recognized by CRBN might be ubiquitinated and degraded by proteasomes. Proteasome-mediated degradation of unneeded or damaged proteins plays a very important role in maintaining regular function of a cell, such as cell survival, dividing, proliferation and growth. Intriguingly, a new role for CRBN has been identified, i.e, the binding of immunomodulatory drugs (IMiDs), e.g. thalidomide, to CRBN has now been associated with teratogenicity and also the cytotoxicity of IMiDs, including lenalidomide, which are widely used to treat multiple myeloma patients. CRBN likely plays an important role in binding, ubiquitination and degradation of factors involved in maintaining function of myeloma cells. These new findings regarding the role of CRBN in IMiD action will stimulate intense investigation of CRBN's downstream factors involved in maintaining regular function of a cell.

Entities:  

Keywords:  AMPK; BKCa; CRBN; ClC-2; Cul4A; DDB1; E3 ubiquitin ligase

Year:  2011        PMID: 22003441      PMCID: PMC3193296     

Source DB:  PubMed          Journal:  Int J Biochem Mol Biol        ISSN: 2152-4114


  64 in total

1.  A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation.

Authors:  Joseph J Higgins; Joanna Pucilowska; Roni Q Lombardi; John P Rooney
Journal:  Neurology       Date:  2004-11-23       Impact factor: 9.910

2.  Histone H3 and H4 ubiquitylation by the CUL4-DDB-ROC1 ubiquitin ligase facilitates cellular response to DNA damage.

Authors:  Hengbin Wang; Ling Zhai; Jun Xu; Heui-Yun Joo; Sarah Jackson; Hediye Erdjument-Bromage; Paul Tempst; Yue Xiong; Yi Zhang
Journal:  Mol Cell       Date:  2006-05-05       Impact factor: 17.970

3.  CSA-dependent degradation of CSB by the ubiquitin-proteasome pathway establishes a link between complementation factors of the Cockayne syndrome.

Authors:  Regina Groisman; Isao Kuraoka; Odile Chevallier; Nogaye Gaye; Thierry Magnaldo; Kiyoji Tanaka; Alexei F Kisselev; Annick Harel-Bellan; Yoshihiro Nakatani
Journal:  Genes Dev       Date:  2006-06-01       Impact factor: 11.361

Review 4.  AMP-activated protein kinase: possible target for treatment of type 2 diabetes.

Authors:  W W Winder
Journal:  Diabetes Technol Ther       Date:  2000       Impact factor: 6.118

5.  Dysregulation of large-conductance Ca2+-activated K+ channel expression in nonsyndromal mental retardation due to a cereblon p.R419X mutation.

Authors:  Joseph J Higgins; Jin Hao; Barry E Kosofsky; Anjali M Rajadhyaksha
Journal:  Neurogenetics       Date:  2008-04-15       Impact factor: 2.660

Review 6.  Regulation of cardiac long-chain fatty acid and glucose uptake by translocation of substrate transporters.

Authors:  Joost J F P Luiken; Susan L M Coort; Debby P Y Koonen; Dick J van der Horst; Arend Bonen; Antonio Zorzano; Jan F C Glatz
Journal:  Pflugers Arch       Date:  2004-02-10       Impact factor: 3.657

7.  First thalidomide clinical trial in multiple myeloma: a decade.

Authors:  Frits van Rhee; Madhav Dhodapkar; John D Shaughnessy; Elias Anaissie; David Siegel; Antje Hoering; Jerome Zeldis; Bonnie Jenkins; Seema Singhal; Jayesh Mehta; John Crowley; Sundar Jagannath; Bart Barlogie
Journal:  Blood       Date:  2008-05-23       Impact factor: 22.113

Review 8.  Role of Akt substrate of 160 kDa in insulin-stimulated and contraction-stimulated glucose transport.

Authors:  Gregory D Cartee; Jørgen F P Wojtaszewski
Journal:  Appl Physiol Nutr Metab       Date:  2007-06       Impact factor: 2.665

9.  Ddb1 is required for the proteolysis of the Schizosaccharomyces pombe replication inhibitor Spd1 during S phase and after DNA damage.

Authors:  Tanya Bondar; Aleksandr Ponomarev; Pradip Raychaudhuri
Journal:  J Biol Chem       Date:  2003-12-29       Impact factor: 5.157

10.  Intrasteric control of AMPK via the gamma1 subunit AMP allosteric regulatory site.

Authors:  Julian Adams; Zhi-Ping Chen; Bryce J W Van Denderen; Craig J Morton; Michael W Parker; Lee A Witters; David Stapleton; Bruce E Kemp
Journal:  Protein Sci       Date:  2004-01       Impact factor: 6.725

View more
  19 in total

Review 1.  Cereblon in health and disease.

Authors:  Hyoung Kyu Kim; Tae Hee Ko; Bayalagmaa Nyamaa; Sung Ryul Lee; Nari Kim; Kyung Soo Ko; Byoung Doo Rhee; Chul-Seung Park; Bernd Nilius; Jin Han
Journal:  Pflugers Arch       Date:  2016-06-24       Impact factor: 3.657

2.  Rescue of Learning and Memory Deficits in the Human Nonsyndromic Intellectual Disability Cereblon Knock-Out Mouse Model by Targeting the AMP-Activated Protein Kinase-mTORC1 Translational Pathway.

Authors:  Charlotte C Bavley; Richard C Rice; Delaney K Fischer; Amanda K Fakira; Maureen Byrne; Maria Kosovsky; Bryant K Rizzo; Dolores Del Prete; Armin Alaedini; Jose A Morón; Joseph J Higgins; Luciano D'Adamio; Anjali M Rajadhyaksha
Journal:  J Neurosci       Date:  2018-02-19       Impact factor: 6.167

3.  A unique carboxyl-terminal insert domain in the hematopoietic-specific, GTPase-deficient Rho GTPase RhoH regulates post-translational processing.

Authors:  Anja Troeger; Hee-Don Chae; Mumine Senturk; Jenna Wood; David A Williams
Journal:  J Biol Chem       Date:  2013-11-04       Impact factor: 5.157

Review 4.  Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.

Authors:  Xiubao Chang; Yuanxiao Zhu; Changxin Shi; A Keith Stewart
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2013-12-29       Impact factor: 3.848

5.  Structural dynamics of the cereblon ligand binding domain.

Authors:  Marcus D Hartmann; Iuliia Boichenko; Murray Coles; Andrei N Lupas; Birte Hernandez Alvarez
Journal:  PLoS One       Date:  2015-05-29       Impact factor: 3.240

6.  Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.

Authors:  Shang-Yi Huang; Chung-Wu Lin; Hsiu-Hsia Lin; Ming Yao; Jih-Luh Tang; Shang-Ju Wu; Yao-Chang Chen; Hsiao-Yun Lu; Hsin-An Hou; Chien-Yuan Chen; Wen-Chien Chou; Woei Tsay; Sheng-Je Chou; Hwei-Fang Tien
Journal:  Ann Hematol       Date:  2014-04-01       Impact factor: 3.673

7.  Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat.

Authors:  Jin-Ya Wang; Ya-Ni Huang; Chong-Chi Chiu; David Tweedie; Weiming Luo; Chaim G Pick; Szu-Yi Chou; Yu Luo; Barry J Hoffer; Nigel H Greig; Jia-Yi Wang
Journal:  J Neuroinflammation       Date:  2016-06-28       Impact factor: 8.322

8.  Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41.

Authors:  Ashley A Basiorka; Kathy L McGraw; Leentje De Ceuninck; Lori N Griner; Ling Zhang; Justine A Clark; Gisela Caceres; Lubomir Sokol; Rami S Komrokji; Gary W Reuther; Sheng Wei; Jan Tavernier; Alan F List
Journal:  Cancer Res       Date:  2016-04-06       Impact factor: 12.701

9.  Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma.

Authors:  Roberta Martiniani; Valentina Di Loreto; Chiara Di Sano; Alessandra Lombardo; Anna Marina Liberati
Journal:  Adv Hematol       Date:  2012-08-02

10.  Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.

Authors:  Qinqin Xu; Yue-xian Hou; Paul Langlais; Patrick Erickson; James Zhu; Chang-Xin Shi; Moulun Luo; Yuanxiao Zhu; Ye Xu; Lawrence J Mandarino; Keith Stewart; Xiu-bao Chang
Journal:  BMC Cancer       Date:  2016-05-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.